Reyataz Articles
European Commission OKs Novartis’ Rasitrio and new label for Bristol-Myers’ Reyataz
28 November 2011
Bristol-Myers Squibb relents on AIDS drug pricing following sustained AHF advocacy campaign
13 August 2010
Bristol-Myers Squibb’s Orencia gets expanded indication in Europe and Reyataz cleared for pediatric use
8 July 2010
Europe’s CHMP updates on pandemic vaccines, backs use extensions for Reyataz and RoActemra, concludes Seroquel XR arbitration
26 April 2010
Bristol-Myers Squibb forecasts large jump in 2010 profit to range of $1.94 to $2.04 per share
29 January 2010
Bristol-Myers sees 64% leap in 3rd quarter 2009 ongoing earnings
23 October 2009
B-MS' 1st qtr hit by tax and legal costs
29 April 2009
Scottish regulators give nod to Bayer's Xarelto, Wyeth's Relistor and B-MS' Reyataz
15 December 2008
Strong 96-week efficacy for B-MS' Reyataz
3 November 2008
Bristol-Myers Squibb's 3rd-qtr 2008 profit triples due to big gain from $4.1B sales of ConvaTec
3 November 2008
US FDA has approved Reyataz plus ritonavir combo for HIV-1
13 October 2008
Reyataz comparable to lopinavir in both genders
18 August 2008
B-MS' profit accelerates on good exchange rate
4 August 2008
EC clears new use for B-MS' Reyataz
30 June 2008
B-MS restructure cuts into 1st-qtr profit
5 May 2008
B-MS' Reyataz/r non-inferior to lopinavir/r
18 February 2008
Plavix rebound cuts B-MS' 4th-qtr 2007 loss and offsets $797M charge
11 February 2008
Boeh Ingl initiates US Viramune study
10 December 2007
Encouraging data for GSK's Lexiva
6 August 2007
Canadian regulators clear 300mg Reyataz
28 May 2007
B-MS swings to loss in 4th qtr due to Plavix
5 February 2007
B-MS's earnings hit $714M in 1st-qtr
8 May 2006
Aspen licenses B-M S HIV drug
27 February 2006
4th-qtr 2005 sales drop 1% for B-MS, as patents lost
30 January 2006
EC allows durable efficacy data for Reyataz label
30 January 2006
B-MS 1st-qtr 2005 income down 36%
9 May 2005
B-MS' Reyataz launched in UK
22 March 2004
B-MS' Reyataz cleared by EC for HIV infection
15 March 2004
20% pharma sales rise boosts B-MS profits
9 February 2004
New Chemical Entities in 2003
19 January 2004
B-MS gets FDA OK for Reyataz
30 June 2003
B-MS' Reyataz for HIV
19 May 2003
Showing 1-46 of 46 articles
- 1
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
